[{"id":"53b6f0a4-0edd-461e-b592-dd05639c4d2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02237157","created_at":"2021-01-18T10:29:50.613Z","updated_at":"2024-07-02T16:36:30.604Z","phase":"Phase 1","brief_title":"A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer","source_id_and_acronym":"NCT02237157","lead_sponsor":"RenovoRx","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • RenovoGem (gemcitabine with RenovoCath)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2021-05-07"}]